TapewireFind a company

person · Reporting owner

Gassert Chad

Disclosed activity across 1 company

Tapewire entity
64059
SEC CIK
0001871002

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ANI PHARMACEUTICALS INCANIP · Entity 4638SVP - CORP. DEV. & STRATEGYFebruary 26, 2026March 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ANI PHARMACEUTICALS INC

Report date February 26, 2026 · Filed March 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect74,916 Ending reported balance After 2026-02-28 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-02-26 · Grant · Acquired 11,116 · Balance 77,137

F1: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

Row 2 · 2026-02-28 · Tax withholding · Disposed 2,221 · Balance 74,916

F2: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Common StockSEC Table I · non-derivativeIndirectHeld by Chali Properties LLC158,490 Reported balance Holding disclosure · report date 2026-02-26 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 158,490

F3: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

F2: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

F3: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 28, 2026 Filed Mar 2, 2026 22:58 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 Tax withholdingCommon Stock 2,221 $73.90 $164,131.90
Disclosure

SEC source: 0001871002-26-000006 · wk-form4_1772492300.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,916

F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 26, 2026 Filed Mar 2, 2026 22:58 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 GrantCommon Stock 11,116 $77.15 $857,599.40
Disclosure

SEC source: 0001871002-26-000006 · wk-form4_1772492300.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,137

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

Read SEC document
February 14, 2026 Filed Feb 17, 2026 21:05 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 Tax withholdingCommon Stock 1,717 $77.36 $132,827.12
Disclosure

SEC source: 0001871002-26-000004 · wk-form4_1771362348.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,021

F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,355 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Read SEC document
February 12, 2026 Filed Feb 17, 2026 21:05 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 Tax withholdingCommon Stock 1,608 $76.70 $123,333.60
Disclosure

SEC source: 0001871002-26-000004 · wk-form4_1771362348.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,738

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,590 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:12 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 Tax withholdingCommon Stock 4,269 $76.25 $325,511.25
Disclosure

SEC source: 0001871002-26-000002 · wk-form4_1771017125.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,346

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023.

Read SEC document
November 13, 2025 Filed Nov 14, 2025 21:30 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 94 $88.00 $8,272.00
Disclosure

SEC source: 0001871002-25-000007 · wk-form4_1763155816.xml · nonDerivative · entry 3

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 158,490

F2 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 21:30 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 14,642 $89.07 $1,304,162.94
Disclosure

SEC source: 0001871002-25-000007 · wk-form4_1763155816.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 158,584

F1 · price: The shares were sold in multiple trades at prices ranging from $89.00 to $89.50. The price reported above reflects the weighted average sales price.

F2 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
August 15, 2025 Filed Aug 18, 2025 20:29 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $86.97 $1,739,400.00
Disclosure

SEC source: 0001871002-25-000004 · wk-form4_1755548946.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 173,226

F1 · price: The shares were sold in multiple trades at prices ranging from $86.54 to $88.05. The price reported above reflects the weighted average sales price.

F2 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:14 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 GrantCommon Stock 9,574 $0.00 $0.00
Disclosure

SEC source: 0001871002-25-000002 · wk-form4_1739927639.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,615

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 12, 2025 Filed Feb 19, 2025 01:14 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 GrantCommon Stock 14,362 $0.00 $0.00
Disclosure

SEC source: 0001871002-25-000002 · wk-form4_1739927639.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,041

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 00:58 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $63.44 $1,268,800.00
Disclosure

SEC source: 0001871002-24-000014 · wk-form4_1719968317.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 193,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2023.

F2 · price: The shares were sold in multiple trades at prices ranging from $62.81 to $64.11. The price reported above reflects the weighted average sales price.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
June 03, 2024 Filed Jun 4, 2024 22:08 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $64.41 $1,288,200.00
Disclosure

SEC source: 0001871002-24-000012 · wk-form4_1717538875.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 213,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2023.

F2 · price: The shares were sold in multiple trades at prices ranging from $63.35 to $65.40. The price reported above reflects the weighted average sales price.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
May 01, 2024 Filed May 3, 2024 21:48 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $66.62 $1,332,400.00
Disclosure

SEC source: 0001871002-24-000010 · wk-form4_1714772885.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 233,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2023.

F2 · price: The shares were sold in multiple trades at prices ranging from $66.05 to $67.30. The price reported above reflects the weighted average sales price.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
April 01, 2024 Filed Apr 2, 2024 22:59 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $67.25 $1,345,000.00
Disclosure

SEC source: 0001871002-24-000008 · wk-form4_1712098747.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 253,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2023.

F2 · price: The shares were sold in multiple trades at prices ranging from $66.50 to $69.05. The price reported above reflects the weighted average sales price.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 20:44 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $65.81 $1,316,200.00
Disclosure

SEC source: 0001871002-24-000006 · wk-form4_1710362669.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 273,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2023.

F2 · price: The shares were sold in multiple trades at prices ranging from $65.23 to $66.34. The price reported above reflects the weighted average sales price.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 22:01 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 Tax withholdingCommon Stock 1,635 $67.67 $110,640.45
Disclosure

SEC source: 0001871002-24-000004 · wk-form4_1709330494.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,679

F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,342 shares of restricted stock, the grant of which was previously reported.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:34 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 GrantCommon Stock 8,946 $0.00 $0.00
Disclosure

SEC source: 0001871002-24-000002 · wk-form4_1708119272.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,314

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 21:34 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 GrantCommon Stock 13,421 $0.00 $0.00
Disclosure

SEC source: 0001871002-24-000002 · wk-form4_1708119272.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,368

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024.

Read SEC document
October 02, 2023 Filed Oct 4, 2023 00:00 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $56.48 $1,129,600.00
Disclosure

SEC source: 0001871002-23-000009 · wk-form4_1696377605.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 293,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F2 · price: Reflects the weighted average price of sales on October 2, 2023. The shares were sold in multiple transactions at prices ranging from $55.90 to $57.66, inclusive.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
September 01, 2023 Filed Sep 5, 2023 21:06 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $64.70 $1,294,000.00
Disclosure

SEC source: 0001871002-23-000006 · wk-form4_1693947949.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 313,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F2 · price: Reflects the weighted average price of sales on September 1, 2023. The shares were sold in multiple transactions at prices ranging from $64.18 to $65.26, inclusive.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
August 01, 2023 Filed Aug 3, 2023 22:03 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $51.06 $1,021,200.00
Disclosure

SEC source: 0001871002-23-000004 · wk-form4_1691100197.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 333,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F2 · price: Reflects the weighted average price of sales on August 1, 2023. The shares were sold in multiple transactions at prices ranging from $50.52 to $52.33, inclusive.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
July 03, 2023 Filed Jul 6, 2023 20:15 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $53.43 $1,068,600.00
Disclosure

SEC source: 0001104659-23-078742 · tm2320740-1_4seq1.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 353,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F2 · price: Reflects the weighted average price of sales on July 3, 2023. The shares were sold in multiple transactions at prices ranging from $52.76 to $54.10, inclusive.

F3 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
June 22, 2023 Filed Jun 24, 2023 00:00 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 SaleCommon Stock 20,000 $51.32 $1,026,400.00
Disclosure

SEC source: 0001104659-23-074398 · tm2319615-1_4seq1.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Plan reported

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 373,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F2 · ownership.nature: The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
February 28, 2023 Filed Apr 5, 2023 00:03 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 GrantCommon Stock 11,578 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-041729 · tm2311710-4_4seq1.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,947

F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

Read SEC document
February 28, 2023 Filed Apr 5, 2023 00:03 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 GrantCommon Stock 17,369 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-041729 · tm2311710-4_4seq1.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,369

F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 28, 2023.

Read SEC document
March 21, 2022 Filed Mar 22, 2022 21:37 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 PurchaseCommon Stock 5,000 $27.87 $139,342.50
Disclosure

SEC source: 0001415889-22-003267 · form4-03222022_020338.xml · nonDerivative · entry 2

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 393,226

F3 · price: The shares were acquired in multiple trades at prices ranging from $27.69 to $28.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The Reporting Person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
March 18, 2022 Filed Mar 22, 2022 21:37 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 PurchaseCommon Stock 5,000 $27.15 $135,744.00
Disclosure

SEC source: 0001415889-22-003267 · form4-03222022_020338.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 388,226

F1 · price: The shares were acquired in multiple trades at prices ranging from $27.06 to $27.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The Reporting Person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document
November 19, 2021 Filed Nov 23, 2021 21:44 UTC ANI PHARMACEUTICALS INC ANIP · Entity 4638 GrantCommon Stock 383,226 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-21-005442 · form4-11232021_011133.xml · nonDerivative · entry 1

Gassert Chad · CIK 0001871002 · SVP - CORP. DEV. & STRATEGY

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Chali Properties LLC

Disclosed balance after: 383,226

F1 · price: On November 19, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of March 8, 2021 (as amended, supplemented or modified from time to time, the "Merger Agreement"), by and among ANI Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), Novitium Pharma LLC, a Delaware limited liability company ("Novitium"), and the other parties thereto, the Issuer completed its acquisition of Novitium. In accordance with the Merger Agreement, an aggregate of 2,000,000 Company Interests of Novitium held by Chali Properties LLC were converted into 383,226 shares of Common Stock of the Issuer. The issuance of the shares was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F2 · ownership.nature: The Reporting Person holds voting and dispositive power over the shares held by Chali Properties LLC.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.